JP4047010B2 - ピリド〔２，３−ｄ〕ピリミジン−２，７−ジアミンキナーゼ阻害剤 - Google Patents

ピリド〔２，３−ｄ〕ピリミジン−２，７−ジアミンキナーゼ阻害剤 Download PDF

Info

Publication number
JP4047010B2
JP4047010B2 JP2001561006A JP2001561006A JP4047010B2 JP 4047010 B2 JP4047010 B2 JP 4047010B2 JP 2001561006 A JP2001561006 A JP 2001561006A JP 2001561006 A JP2001561006 A JP 2001561006A JP 4047010 B2 JP4047010 B2 JP 4047010B2
Authority
JP
Japan
Prior art keywords
pyrimidin
pyrido
urea
piperazin
ylphenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001561006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003523357A (ja
Inventor
ブース，リチャード・ジョン
ドブルシン，エレン・マイラ
ジョシュラ，ヴァラ・プラサド・ヴェンカタ・ナジェンドラ
マクナマラ，デニス・ジョゼフ
トゥーグッド，ピーター・ローレンス
Original Assignee
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー filed Critical ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー
Publication of JP2003523357A publication Critical patent/JP2003523357A/ja
Application granted granted Critical
Publication of JP4047010B2 publication Critical patent/JP4047010B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2001561006A 2000-01-25 2001-01-23 ピリド〔２，３−ｄ〕ピリミジン−２，７−ジアミンキナーゼ阻害剤 Expired - Fee Related JP4047010B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25
US60/178,261 2000-01-25
PCT/IB2001/000069 WO2001055147A1 (en) 2000-01-25 2001-01-23 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
JP2003523357A JP2003523357A (ja) 2003-08-05
JP4047010B2 true JP4047010B2 (ja) 2008-02-13

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001561006A Expired - Fee Related JP4047010B2 (ja) 2000-01-25 2001-01-23 ピリド〔２，３−ｄ〕ピリミジン−２，７−ジアミンキナーゼ阻害剤

Country Status (34)

Country Link
EP (1) EP1254137A1 (cs)
JP (1) JP4047010B2 (cs)
KR (1) KR20020065939A (cs)
CN (1) CN1395578A (cs)
AP (1) AP2002002586A0 (cs)
AR (1) AR030044A1 (cs)
AU (1) AU2542501A (cs)
BG (1) BG106850A (cs)
BR (1) BR0107751A (cs)
CA (1) CA2397961C (cs)
CO (1) CO5261549A1 (cs)
CR (1) CR6706A (cs)
CZ (1) CZ20022475A3 (cs)
DZ (1) DZ3266A1 (cs)
EA (1) EA200200643A1 (cs)
EE (1) EE200200405A (cs)
GT (1) GT200100016A (cs)
HN (1) HN2001000013A (cs)
HU (1) HUP0204141A3 (cs)
IL (1) IL150545A0 (cs)
IS (1) IS6443A (cs)
MA (1) MA26868A1 (cs)
MX (1) MXPA02007221A (cs)
NO (1) NO20023527L (cs)
OA (1) OA12161A (cs)
PA (1) PA8510701A1 (cs)
PE (1) PE20011066A1 (cs)
PL (1) PL356802A1 (cs)
SK (1) SK10632002A3 (cs)
SV (1) SV2002000294A (cs)
TN (1) TNSN01014A1 (cs)
WO (1) WO2001055147A1 (cs)
YU (1) YU50402A (cs)
ZA (1) ZA200205879B (cs)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ES2372028T3 (es) 2000-10-23 2012-01-13 Glaxosmithkline Llc Nuevo compuesto de 8h-pirido[2,3-d]pirimidin-7-ona trisustituida para el tratamiento de enfermedades mediadas por la csbp/p38 quinasa.
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
MXPA04010267A (es) 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
KR20050084027A (ko) * 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
CA2579406A1 (en) * 2004-09-21 2006-03-30 F.Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors
JP2008535822A (ja) 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
PE20100741A1 (es) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
EP1865959A2 (en) 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
CN101243081A (zh) * 2005-07-21 2008-08-13 霍夫曼-拉罗奇有限公司 作为PTP1B抑制剂的吡啶并[2,3-d]嘧啶-2,4-二胺化合物
AU2006279992A1 (en) 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
BRPI0922154A2 (pt) * 2008-12-01 2016-01-05 Merck Patent Gmbh pirido[4,3-d]pirimidinas 2,5-diamino-substituídas como inibidores de autotaxina contra o cãncer
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
US9815847B2 (en) 2013-03-14 2017-11-14 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711426B2 (en) * 1994-11-14 1999-10-14 Warner-Lambert Company 6-aryl pyrido(2,3-d)pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
BR9911590A (pt) * 1998-05-26 2001-02-13 Warner Lambert Co Pirimidinas bicìclicas e 3,4-diidropirimidinas bicìclicas como inibidores da proliferação celular

Also Published As

Publication number Publication date
MA26868A1 (fr) 2004-12-20
CR6706A (es) 2005-04-04
DZ3266A1 (fr) 2001-08-02
NO20023527L (no) 2002-09-10
BG106850A (bg) 2003-02-28
PL356802A1 (en) 2004-07-12
PA8510701A1 (es) 2002-12-11
CZ20022475A3 (cs) 2003-03-12
ZA200205879B (en) 2003-09-29
PE20011066A1 (es) 2001-10-22
GT200100016A (es) 2001-10-19
EP1254137A1 (en) 2002-11-06
IS6443A (is) 2002-06-25
EE200200405A (et) 2003-12-15
TNSN01014A1 (fr) 2005-11-10
CO5261549A1 (es) 2003-03-31
CA2397961A1 (en) 2001-08-02
EA200200643A1 (ru) 2002-12-26
KR20020065939A (ko) 2002-08-14
SK10632002A3 (sk) 2003-06-03
YU50402A (sh) 2005-11-28
AU2542501A (en) 2001-08-07
JP2003523357A (ja) 2003-08-05
AR030044A1 (es) 2003-08-13
NO20023527D0 (no) 2002-07-24
IL150545A0 (en) 2003-02-12
HUP0204141A2 (hu) 2003-04-28
SV2002000294A (es) 2002-07-16
OA12161A (en) 2006-05-08
MXPA02007221A (es) 2002-11-29
BR0107751A (pt) 2002-11-12
HN2001000013A (es) 2001-06-18
CA2397961C (en) 2008-08-26
CN1395578A (zh) 2003-02-05
HUP0204141A3 (en) 2005-03-29
AP2002002586A0 (en) 2002-09-30
WO2001055147A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
JP4047010B2 (ja) ピリド〔２，３−ｄ〕ピリミジン−２，７−ジアミンキナーゼ阻害剤
US12171739B2 (en) N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
US7053070B2 (en) Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
AU777468B2 (en) Pteridinones as kinase inhibitors
AU763839B2 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
JP5400626B2 (ja) 置換イミダゾおよびトリアゾロピリミジン類
US8697692B2 (en) Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
US20100069395A1 (en) Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors
SK12472002A3 (sk) 5-Alkylpyrido[2,3-d]pyrimidínové inhibítory tyrosínových kináz
JP2012136537A (ja) キナゾリン化合物
CZ286160B6 (cs) 6-Arylpyrido[2,3-d]pyrimidiny a naftyridiny a farmaceutické prostředky na jejich bázi
JP2008519790A (ja) キナーゼ阻害剤としての１，４−置換ピラゾロピリミジン

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20061124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20061211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070327

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071121

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101130

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees